BAP1 regulates HSF1 activity and cancer immunity in pancreatic cancer
Our study elucidates an unrevealed mechanism by which BAP1 regulates immune therapy response in PDAC via HSF1 inhibition, and providing promising therapeutic strategies to address immune insensitivity in BAP1-deficient PDAC.
Authors
- Wentao Xia (ORCID: https://orcid.org/0000-0003-4793-4188)
- Yanshen Liu
- Yuhan Zhao (ORCID: https://orcid.org/0000-0001-5529-1907)
- Taoyu Chen (ORCID: https://orcid.org/0000-0002-8966-1264)
- Qiyue Zhang (ORCID: https://orcid.org/0000-0002-1916-9506)
- J. Huang (ORCID: https://orcid.org/0009-0007-4894-4659)
- Shilin Yin
- Zhiqiang Liu (ORCID: https://orcid.org/0000-0003-2982-8381)
- Gaofeng Li (ORCID: https://orcid.org/0000-0003-0584-431X)
- Xueyi Liang (ORCID: https://orcid.org/0000-0002-7075-4030)
- Weiwei Yuan (ORCID: https://orcid.org/0009-0004-2686-6918)
Institutions
- Union Hospital (HK)
- Zhengzhou University (CN)
- Wuhan Union Hospital (CN)
- Henan Cancer Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1186/s13046-024-03196-4
- Citations
- 5
- Primary Topic
- Endoplasmic Reticulum Stress and Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- National Natural Science Foundation of China